Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells

Cancer Gene Therapy volume 19, pages 845–851 (2012)Cite this article

Subjects

Abstract

Colorectal carcinoma is one of the most frequent cancer diseases. For patients with this type of cancer, liver metastases are the main cause of death. Therefore, new therapeutic approaches are urgently needed to improve the outcomes. We found that both mRNA and protein levels of tissue inhibitor of metalloproteinase-3 (TIMP3) were decreased significantly in colorectal cancer tissue when compared with normal mucosa, suggesting that decrease of TIMP3 expression was correlated with malignant behavior of colorectal cancer. We evaluated the power of TIMP3, a new potent multiple functional molecule, as a biotheropeutic tool to treat cancer. Adenovirus-mediated TIMP3 transduction in CT26 colon cancer model demonstrated multiple effects to arrest cancer cell growth and induced massive apoptosis. Also, adenovirally transferred TIMP3 reduced adhesion, migration and invasion behaviors of CT26 cells in vitro. In vivo data showed that TIMP3 suppressed in vivo tumor growth and that liver metastasis was significantly reduced by TIMP3 transduction. This is the first systematic preclinical study to show that TIMP3 may be a potential molecular tool for colon cancer biological therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y . Colorectal cancer: genetics of development and metastasis. J Gastroenterol 2006; 41: 185–192.

    Article  CAS  PubMed  Google Scholar 

  2. Powe DG, Brough JL, Carter GI, Bailey EM, Stetler-Stevenson WG, Turner DR et al. TIMP3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer 1997; 75: 1678–1683.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Mino N, Takenaka K, Sonobe M, Miyahara R, Yanagihara K, Otake Y et al. Expression of tissue inhibitor of metalloproteinase-3 (TIMP3) and its prognostic significance in resected non-small cell lung cancer. J Surg Oncol 2007; 95: 250–257.

    Article  CAS  PubMed  Google Scholar 

  4. Zhang H, Wang YS, Han G, Shi Y . TIMP3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. Hepatobiliary Pancreat Dis Int 2007; 6: 487–491.

    CAS  PubMed  Google Scholar 

  5. Zhang Y, Qian H, Lin C, Lang J, Xiang Y, Fu M et al. Adenovirus carrying TIMP3: a potential tool for cervical cancer treatment. Gynecol Oncol 2008; 108: 234–240.

    Article  CAS  PubMed  Google Scholar 

  6. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9: 407–415.

    Article  CAS  PubMed  Google Scholar 

  7. Chen Y, Qian H, Zhang Y, Ma Y, Lin C, Xiang Y . Effect of Ad-TIMP3 on biologic behavior of choriocarcinoma cells in vitro. J Reprod Med 2008; 53: 608–614.

    CAS  PubMed  Google Scholar 

  8. Li F, Curry TE . Regulation and function of tissue inhibitor of metalloproteinase (TIMP) 1 and TIMP3 in periovulatory rat granulosa cells. Endocrinology 2009; 150: 3903–3912.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Qian H, Lu N, Xue L, Liang X, Zhang X, Fu M et al. Reduced MTA1 expression by RNAi inhibits in vitro invasion and migration of esophageal squamous cell carcinoma cell line. Clin Exp Metastasis 2005; 22: 653–662.

    Article  CAS  PubMed  Google Scholar 

  10. TIMP3, angiogenesis and macular degeneration. Matrix Biol 2008; 27: 379–380.

  11. Anania MC, Sensi M, Radaelli E, Miranda C, Vizioli MG, Pagliardini S et al. TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. Oncogene 2011; 30: 3011–3023.

    Article  CAS  PubMed  Google Scholar 

  12. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K et al. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis Colon Rectum 2011; 54: 1026–1035.

    Article  PubMed  Google Scholar 

  13. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59: 798–802.

    CAS  PubMed  Google Scholar 

  14. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC . Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP3. Br J Cancer 1999; 79: 1347–1355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Finan KM, Hodge G, Reynolds AM, Hodge S, Holmes MD, Baker AH et al. In vitro susceptibility to the pro-apoptotic effects of TIMP3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer 2006; 53: 273–284.

    Article  PubMed  Google Scholar 

  16. Bernot D, Barruet E, Poggi M, Bonardo B, Alessi MC, Peiretti F . Down-regulation of tissue inhibitor of metalloproteinase-3 (TIMP3) expression is necessary for adipocyte differentiation. J Biol Chem 2010; 285: 6508–6514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C et al. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem 2010; 116: 63–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Masson D, Rioux-Leclercq N, Fergelot P, Jouan F, Mottier S, Théoleyre S et al. Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur J Cancer 2010; 46: 1430–1437.

    Article  CAS  PubMed  Google Scholar 

  19. Ninomiya I, Kawakami K, Fushida S, Fujimura T, Funaki H, Takamura H et al. Quantitative detection of TIMP3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep 2008; 20: 1489–1495.

    CAS  PubMed  Google Scholar 

  20. Kallio JP, Hopkins-Donaldson S, Baker AH, Kahari VM . TIMP3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway. Int J Cancer 2011; 128: 991–996.

    Article  CAS  PubMed  Google Scholar 

  21. Bond M, Murphy G, Bennett MR, Newby AC, Baker AH . Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 2002; 277: 13787–13795.

    Article  CAS  PubMed  Google Scholar 

  22. Zucker S, Cao J, Chen WT . Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 6642–6650.

    Article  CAS  PubMed  Google Scholar 

  23. Kruger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V et al. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 2001; 61: 1272–1275.

    CAS  PubMed  Google Scholar 

  24. Coussens LM, Fingleton B, Matrisian LM . Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387–2392.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The project was supported by grants from the National Basic Research Program of China (973 Program) (2009CB521807). We thank them for the support provided.

Author information

Authors and Affiliations

  1. Department of Gastroenterology Surgery, Peking University People’s Hospital, Beijing, China

    H Lin, Y Ye & S Wang

  2. Department of General Surgery, First Hospital of Tsinghua University, Beijing, China

    H Lin

  3. Department of Gynecology, Minimal Invasive Center, Beijing Obstetrics and Gynecology Hospital, Capital University of Medical Sciences, Beijing, China

    Y Zhang

  4. State Key Laboratory of Molecular Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China

    H Wang, D Xu, X Meng, Y Shao, C Lin & H Qian

Authors
  1. H Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Y Ye, H Qian or S Wang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, H., Zhang, Y., Wang, H. et al. Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells. Cancer Gene Ther 19, 845–851 (2012). https://doi.org/10.1038/cgt.2012.70

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2012.70

Keywords

This article is cited by

Search

Advanced search

Quick links